United Therapeutics
UTHR
472 hedge funds and large institutions have $10.4B invested in United Therapeutics in 2022 Q2 according to their latest regulatory filings, with 93 funds opening new positions, 149 increasing their positions, 158 reducing their positions, and 41 closing their positions.
151% more call options, than puts
Call options by funds: $75.3M | Put options by funds: $30M
127% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 41
71% more funds holding in top 10
Funds holding in top 10: 14 → 24 (+10)
31% more capital invested
Capital invested by funds: $7.91B → $10.4B (+$2.49B)
10% more funds holding
Funds holding: 428 → 472 (+44)
0.55% less ownership
Funds ownership: 97.75% → 97.2% (-0.55%)
6% less repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 158
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$87.8M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$36.4M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$34.4M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$28.1M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$26.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$45M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$36M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$35.4M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$34.1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$32.8M |
UTHR Hedge Fund Activity: Q2 2022 in Review
472 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2022, worth a combined $10.4B — up 31% from $7.91B a quarter earlier.
Buyers outnumbered sellers: 93 funds opened new UTHR positions and 41 closed out — a net gain of 52 holders — while 149 added to existing stakes and 158 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $87.8M. The largest seller was Wellington Management Group, cutting an estimated $45M.
- 472 institutional investors held United Therapeutics (UTHR) as of Q2 2022, up from 428 in Q1 2022.
- Funds reported $10.4B of United Therapeutics stock for Q2 2022, up 31% quarter-over-quarter.
- 93 funds opened new United Therapeutics positions in Q2 2022 and 41 closed out, a net change of +52 holders.
- The largest United Therapeutics buyer in Q2 2022 was Assenagon Asset Management, an estimated $87.8M added.
- The largest United Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $45M sold.
Based on aggregated 13F filings for Q2 2022.